<DOC>
	<DOCNO>NCT01280786</DOCNO>
	<brief_summary>This phase 1 study test safety escalate dos elesclomol sodium give patient advanced myeloid leukemia .</brief_summary>
	<brief_title>Study Elesclomol Sodium Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>This aim study determine safety tolerability elesclomol sodium escalating dos ( ultimately identify maximum tolerate dose ) administer patient advanced myeloid leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Adults cytologically confirm Acute Myeloid Leukemia ( AML ) relapse completion induction and/or consolidation therapy fail respond standard induction therapy ECOG performance status 02 Acceptable organ marrow function screen period define protocol Reliable venous access suitable study drug infusion Significant cardiovascular disease Candidates hematopoietic stem cell transplant Women pregnant breastfeed Prior treatment chronic immunosuppressant Other clinically significant uncontrolled condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>leukemia</keyword>
	<keyword>relapsed refractory AML</keyword>
</DOC>